Text Size
1 study found for:    NCT00692770

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
To Top

† Indicates status has not been verified in more than two years